A lower dose of intravitreal bevacizumab effectively treats retinopathy of prematurity

All eyes treated with 0.25mg/0.01ml intravitreal bevacizumab showed complete regression, with no recurrence of plus disease or neovascularization. No safety issues were attributable to bevacizumab during the study period.